Business Parks & Science Centres



SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px
Document › Details

Anagenesis Biotechnologies. (5/18/17). "Press Release: Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to Discover Drugs for Chronic Muscle Diseases". Illkirch Graffenstaden.

Organisations Organisation Anagenesis Biotechnologies (FR)
  Today Anagenesis (Group)
  Group Anagenesis (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product P2MC technology (Paraxial Mesoderm Multipotent Cells)
  Product 2 small-molecule drug
Index term Index term Boehringer–Anagenesis: drug discovery technology, 201705– excl license to P2MC technology for drug developm for chronic muscle diseases

Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases. The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into muscle fibers and adult muscle stem cells, also known as satellite cells. The agreement will support the Boehringer Ingelheim R&D efforts in the discovery of treatments for chronic musculoskeletal diseases such as sarcopenia and cachexia. A High Throughput Screening assay developed by Anagenesis using wild type human muscle progenitors enriched in satellite cells will be used to identify small molecules inducing myogenesis.

“We are excited to partner with Boehringer Ingelheim to advance therapeutic developments for chronic musculoskeletal diseases, where there is a high and growing unmet medical need. We believe our P2MC technology has unique advantages recognized yet again by this new partnership, Boehringer Ingelheim is the third partnership for Anagenesis in the past 18 months, and follows agreements with Ksilink in DMD and CRISPR Therapeutics in cell therapy for muscle diseases.” said Jean-Yves Bonnefoy, PhD, President and Chief Executive Officer of Anagenesis.

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing paraxial mesoderm-derived lineages (striated muscle, brown fat, cartilage, bone, dermis & endothelial cells) to generate new treatments against human diseases. Anagenesis’ proprietary P2MC technology was developed with the support of AFM-telethon, INSERM Transfert, CNRS and Strasbourg University.

The company was cofounded by Dr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is Professor at the Harvard Medical School and the Brigham and Women’s Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. Anagenesis Biotechnologies in Illkirch, France, is focusing on High-Troughput and High-Content screens, while its US subsidiary in Boston, MA, Anagenesis Biotherapies Inc., is developing the cell therapy approaches. For more information, please visit

Jean-Yves Bonnefoy
+33 620 885 092

Record changed: 2017-06-07


Picture [LSE] – The Business Web Portal 600x60px

More documents for Anagenesis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top